Evotec 

€6.03
256
+€0.08+1.26% Wednesday 15:32

統計

當日最高
6.08
當日最低
6
52週最高
22.67
52週最低
5.21
成交量
0
平均成交量
87
市值
3.19B
市盈率
451.38
股息收益率
-
股息
-

即將到來

收益

6Nov預期
Q1 2024
Q2 2024
下一個
-0.53
-0.36
-0.2
-0.04
預期每股收益
-0.0433459653722656
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 EVT.VI 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Show more...
首席執行官
Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D.
員工
4715
國家
DE
ISIN
DE0005664809

上市公司